Portage Biotech Inc (NASDAQ:PRTG) — Market Cap & Net Worth
Market Cap & Net Worth: Portage Biotech Inc (PRTG)
Portage Biotech Inc (NASDAQ:PRTG) has a market capitalization of $10.71 Million ($10.71 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26722 globally and #5324 in its home market, demonstrating a -10.13% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Portage Biotech Inc's stock price $4.70 by its total outstanding shares 2278620 (2.28 Million). Analyse PRTG cash generation efficiency to see how efficiently the company converts income to cash.
Portage Biotech Inc Market Cap History: 2015 to 2025
Portage Biotech Inc's market capitalization history from 2015 to 2025. Data shows change from $597.00 Million to $10.71 Million (-35.05% CAGR).
Index Memberships
Portage Biotech Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #770 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2526 of 3165 |
Weight: Portage Biotech Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Portage Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Portage Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PRTG by Market Capitalization
Companies near Portage Biotech Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Portage Biotech Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Portage Biotech Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Portage Biotech Inc's market cap moved from $597.00 Million to $ 10.71 Million, with a yearly change of -35.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $10.71 Million | -9.09% |
| 2024 | $11.78 Million | -85.80% |
| 2023 | $82.94 Million | -65.59% |
| 2022 | $241.03 Million | -50.71% |
| 2021 | $488.99 Million | -45.23% |
| 2020 | $892.76 Million | +108.40% |
| 2019 | $428.38 Million | -2.08% |
| 2018 | $437.50 Million | -83.59% |
| 2017 | $2.67 Billion | +350.00% |
| 2016 | $592.44 Million | -0.76% |
| 2015 | $597.00 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Portage Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.71 Million USD |
| MoneyControl | $10.71 Million USD |
| MarketWatch | $10.71 Million USD |
| marketcap.company | $10.71 Million USD |
| Reuters | $10.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Portage Biotech Inc
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor … Read more